← Oncology Approval Tracker

FDA DECISION ·

Retevmo

selpercatinib · Eli Lilly

Accelerated approvalNew therapyRET fusion-positive thyroid cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

LATER FDA ACTION

Traditional approval granted on Jun 12, 2024

FDA Project Confirm ↗

APPROVED USE

What FDA approved

Adults and children ages 12 years and older with advanced or metastatic RET fusion-positive thyroid cancer requiring systemic therapy, refractory to radioactive iodine when radioactive iodine was appropriate.

LAMPGEN ANALYSIS

Why it matters

Added a selective RET inhibitor option for thyroid cancers meeting fusion and prior radioiodine criteria.

What research teams should watch

Confirm the fusion and document whether radioactive iodine was appropriate and why the disease was refractory.

PRIMARY RECORDS

Sources